Batoclimab Effective and Safe With Generalized MG, Phase 2 Trial Finds

Batoclimab Effective and Safe With Generalized MG, Phase 2 Trial Finds

299212

Batoclimab Effective and Safe With Generalized MG, Phase 2 Trial Finds

Harbour BioMed’s investigational therapy batoclimab (HBM9161) safely and rapidly eases symptoms and lowers the levels of harmful antibodies in adults with moderate-to-severe generalized myasthenia gravis (gMG), according to top-line data from a Phase 2 clinical trial in China. “The strong evidence generated from this study is quite exciting and further indicates that batoclimab could be a novel therapy with favorable safety profile and substantial clinical improvements,” Jingsong Wang, Harbour’s founder, chairman, and CEO, said in…

You must be logged in to read/download the full post.